Send us a text

Imagine transforming a days-long pathology process into minutes while maintaining or improving diagnostic accuracy. That's exactly what Optiscan Imaging is accomplishing with their groundbreaking miniaturised confocal end microscopy technology.

Dr Camile Farah, CEO and Managing Director of Optiscan, returns to the podcast to unveil Inform – their revolutionary digital pathology device designed specifically for pathologists and pathology labs. This innovative technology captures microscopic-grade images in real-time at 1,000 times the resolution of standard medical imaging, dramatically streamlining workflows between surgeons and pathologists while slashing diagnostic waiting times from days to minutes.

What truly sets Optiscan's approach apart is their comprehensive cloud-based telepathology platform. This system enables surgeons in Melbourne to collaborate instantly with pathologists in Arizona while the patient remains on the operating table. For rural and remote areas, this technology eliminates the need for on-site specialists, democratising access to world-class pathology services regardless of location.

Ready to explore the future of medical imaging? Listen now and discover how Australian innovation is transforming global healthcare one microscopic image at a time.

Send us a text

Fascinating breakthroughs in sustainable construction and climate technology take centre stage as James Marsh, CEO of Zeotech Limited, unveils the company's game-changing innovations. The conversation explores how Zeotech's AusPozz™ product is redefining possibilities in low-carbon concrete, with commercial demonstrations confirming its ability to replace up to 40% of cement while delivering superior strength and dramatically reduced shrinkage.

What makes this technology truly revolutionary is its versatility and comprehensive performance profile. Beyond simple cement replacement, AusPozz™ outperforms expensive additives like silica fume while eliminating the need for various chemical additives that typically address concrete issues like cracking and bleeding. This exceptional value proposition has attracted partnerships with construction giants including Holcim, with strategic agreements positioning Zeotech for seaborne distribution to Sydney and Melbourne concrete markets, as well as global opportunities through Gladstone Ports Corporation's deepwater facilities.

The conversation takes an exciting turn as Marsh details their second horizon: zeolite-based methane remediation technology showing 70-85% efficiency in capturing this potent greenhouse gas. With their pre-feasibility study nearing completion and their current resource representing just 5% of available exploration area, Zeotech stands at the threshold of significant growth. Dive into this episode to discover how Australian innovation is tackling two of our most pressing environmental challenges – carbon-intensive construction and methane emissions – with solutions that don't just match industry standards but dramatically exceed them. Ready to understand the future of sustainable materials? Listen now and gain insights into technology that leading industry experts are calling "a genuine game-changer."

Send us a text

Steve Lydeamore, CEO of Immuron Limited, takes us behind the scenes of one of Australia's most innovative biopharmaceutical companies. What makes this Melbourne-based biotech unique is their dual focus—a thriving commercial product alongside a promising technology platform targeting infectious diseases.

The spotlight falls on Travelan, Immuron's preventative treatment for traveller's diarrhoea that has experienced phenomenal growth. After sales plummeted to near-zero during the pandemic, the company has ssen a remarkable turnaround from $145,000 to over $5.3 million in less than a year. This success story involved strengthening pharmacy distribution networks across Australia and Canada while leveraging Amazon as their primary channel in the US market. As international travel rebounds, particularly to high-risk regions like Bali and Vietnam, Travelan's unique preventative approach—"nobody wants to get it"—positions it perfectly for continued growth.

Send us a text

Critical minerals lie at the heart of the green energy transition, yet many remain under-appreciated by investors. Tin - essential for electronics, solar panels, and batteries - stands out as particularly vulnerable with looming supply shortages and concentrated production far from end users.

Joe David, Managing Director of Elementos Limited, reveals how their company is positioning to address this critical gap through two strategic projects. Their flagship Oropesa project in Spain's Andalusia region recently completed a Definitive Feasibility Study showing remarkable economics: $270 million NPV and 26% IRR using conservative pricing assumptions. For a company valued at just $20 million, this represents substantial potential upside.

What makes Oropesa truly strategic is its position as Europe's only vertically integrated tin mine and smelter. David explains the startling reality that neither Europe nor North America currently have any domestic tin mines, despite being major consumers. By establishing a complete mine-to-metal operation within European borders, Elementos not only addresses geopolitical supply risks but also captures the $1,000 premium that tin commands in European markets compared to standard prices.

Send us a text

Renewable energy and waste transformation converge powerfully in this illuminating conversation with Joe Oliver, Managing Director of Delorean Corporation Limited (ASX:DEL). We explore how this innovative company is revolutionizing Australia's approach to organic waste by converting it into valuable renewable energy through advanced anaerobic digestion technology.

The spotlight shines on Delorean's recent $6 million ARENA grant success, which powerfully validates their business model and accelerates the development of the groundbreaking SA1 facility – Australia's first project injecting biomethane from organic waste into the gas network. Joe reveals the facility's unique dual revenue model that combines renewable gas with food-grade liquid CO2 production, creating diversified cash flow and enhanced returns on capital.

Ready to discover how waste transformation is powering Australia's clean energy revolution? Listen now and see why Delorean Corporation represents one of the most compelling opportunities in the renewable energy sector today. Subscribe to ASX Briefs for more innovative company spotlights and investment insights!

Send us a text

Ever wondered how scientists accurately measure brain health across thousands of patients in dozens of countries speaking 30 different languages? That's exactly what Cogstate has mastered over its 25-year journey to become a leader in neuroscience technology.

Brad O'Connor, CEO of Cogstate Limited, takes us behind the scenes of this fascinating ASX-listed company that's quietly revolutionizing how brain health is measured globally. What began as a digital disruptor creating computerized cognitive assessments has evolved into an essential partner for pharmaceutical companies developing new treatments for conditions like Alzheimer's disease, depression, and rare neurological disorders.

The numbers tell a compelling story of innovation driving efficiency. While many companies struggled during the pandemic, Cogstate found ways to do more with less—reducing their workforce by 25% while simultaneously achieving record revenue growth. Their secret? Strategic implementation of AI and advanced analytics that allow them to manage clinical trial endpoints with unprecedented accuracy and at global scale.

Beyond impressive financials—60% gross margins, 20% EBIT margins, and US$34 million in cash with no debt—it's Cogstate's vision for the future that captivates. O'Connor shares how their technology might soon help everyday people assess their cognitive health from home, similar to using a thermometer before deciding whether to see a doctor. With pharmaceutical spending on central nervous system diseases projected to approach oncology levels within a decade, Cogstate stands at the forefront of a massive market opportunity.

Ready to explore how brain health technology is creating both better patient outcomes and compelling investment opportunities? Listen now to discover why Cogstate's digital cognitive tools are becoming indispensable in both clinical research and healthcare settings worldwide.

Send us a text

Shane Hartwig, Managing Director and CEO of Northern Minerals, reveals how the company is positioning itself at the forefront of Australia's heavy rare earth sector through its flagship Browns Range project. Located in the remote Kimberley region of Western Australia, this strategic asset represents a significant opportunity to develop an Australian-based rare earths supply chain.

The conversation navigates through Northern Minerals' evolution from uranium explorer to rare earth developer, showcasing how the company plans to produce heavy rare earth-rich concentrate for partner Iluka Resources. This strategic partnership creates a powerful alternative to Chinese-dominated supply chains, with Iluka set to process Northern Minerals' concentrate into separated rare earth oxides essential for permanent magnets used in electric vehicles, wind turbines, defense applications, and even emerging humanoid robotics.

Shane details the company's methodical approach to project development, highlighting recent exploration programs at deposits like Dazzler and Gambit while explaining how their systematic review has identified a strong pipeline of prospects to potentially expand their mineral resources. The discussion provides valuable insights into their optimization efforts around CAPEX and OPEX for the feasibility study expected to be completed by the second quarter's end – a critical milestone that will drive funding discussions with government agencies like NAIF and EFA.

Send us a text

Step into the world of one of Australia's most promising precious metals discoveries with Glen Diemar, Managing Director of Australian Gold and Copper (AGC). The company's Achilles discovery in New South Wales is turning heads across the mining sector with extraordinary polymetallic grades—including a jaw-dropping discovery hole featuring 5 meters at nearly 17 g/t gold, 1700 g/t silver, and 15% combined lead and zinc.

What separates AGC from the typical junior explorer is its remarkable financial strength. With $16 million in cash and strong backing from major shareholders GeoZen and New South Resources, the company is executing an exploration program more akin to what you'd expect from a major mining house. This financial firepower enables a comprehensive, multi-discipline approach across an 8-kilometer shear zone that has barely seen modern exploration.

The timing couldn't be better for AGC's silver-dominant system, with precious metals prices reaching record highs week after week. But this story extends far beyond Achilles itself. Glen reveals how the company's systematic exploration could uncover multiple deposits along the shear zone, following the pattern seen throughout the prolific Cobar Basin. Just 130 kilometers north lies the world's third-highest grade copper mine—a tantalizing reminder of the potential prize awaiting successful explorers in this region.